¼¼°èÀÇ ¾ÏÄ¡·á¿ë ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå
Novel Drug Delivery Systems in Cancer Therapy
»óǰÄÚµå : 1799158
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 181 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¾ÏÄ¡·á¿ë ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº 2030³â±îÁö ¹Ì±¹¿¡¼­ 645¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 213¾ï ´Þ·¯·Î ÃßÁ¤µÇÁö¸¸ Ä¡·á¿¡¼­ ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 20.3%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 645¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ³ª³ëÀÔÀÚ´Â CAGR 18.0%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 358¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »öÀü¿ë ÀÔÀÚ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 23.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 58¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 26.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¾ÏÄ¡·á¿ë ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº 2024³â¿¡ 58¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 150¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 26.9%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 16.4%¿Í 18.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 16.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¾ÏÄ¡·á¿ë ½Å±Ô ¾à¹°Àü´Þ ½Ã½ºÅÛ-ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

»õ·Î¿î ¾à¹°Àü´Þ ½Ã½ºÅÛÀÌ ±âÁ¸ÀÇ ¾Ï Ä¡·á¹ýÀ» ÆÄ±«ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

±âÁ¸ È­Çпä¹ýÀº Àü½Å µ¶¼º, ³·Àº »ýü ÀÌ¿ë·ü, Á¾¾ç ƯÀ̼º ºÎÁ· µî Ä¡·á È¿°ú¿Í ȯÀÚÀÇ »îÀÇ ÁúÀ» ÀúÇØÇÏ´Â ¹®Á¦¸¦ ¿À·§µ¿¾È °Þ¾î¿Ô½À´Ï´Ù. NDDS(New Drug Delivery System)´Â °Ç°­ÇÑ Á¶Á÷ ¼Õ»óÀ» ÃÖ¼ÒÈ­Çϸ鼭 Á¾¾ç ºÎÀ§¿¡ Á÷Á¢ Ç×¾ÏÁ¦¸¦ Ç¥Àû Àü´ÞÇÒ ¼ö ÀÖ´Â ±â¼ú·Î, Á¾¾çÇÐ ºÐ¾ßÀÇ Çõ½Å ±â¼ú·Î ±ÞºÎ»óÇϰí ÀÖ½À´Ï´Ù. NDDS´Â ¾àµ¿ÇÐÀ» °³¼±ÇÏ°í ¾àÁ¦ ³»¼º ¸ÞÄ¿´ÏÁòÀ» ±Øº¹ÇÔÀ¸·Î½á ÀÓ»óÀǰ¡ º¹ÀâÇÏ°í ºÒ±ÕÀÏÇÑ ¾ÏÁ¾¿¡ Á¢±ÙÇÏ´Â ¹æ½ÄÀ» ÀçÁ¤ÀÇÇϰí ÀÖ½À´Ï´Ù.

°¡Àå Áß¿äÇÑ Çõ½ÅÀº ¸®Æ÷Á», µ§µå¸®¸Ó, ¹Ì¼¿, °íºÐÀÚ ³ª³ëÀÔÀÚ µîÀÇ ³ª³ë ij¸®¾î·Î, ¼¼Æ÷µ¶¼º ¾à¹°À» ÀÎĸ½¶·¹À̼ÇÇÏ¿© Á¾¾ç ¹Ì¼¼È¯°æ¿¡¼­ Á¦¾îµÈ ¹æÃâÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ³ª³ë ij¸®¾îÀÔ´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº °íÇü Á¾¾ç¿¡¼­ °üÂûµÇ´Â Åõ°ú¼º ¹× ü·ù¼º Çâ»ó(EPR) È¿°ú¸¦ ÀÌ¿ëÇÏ¿© ºÎÀ§ ƯÀÌÀû Àü´ÞÀ» ½ÇÇöÇÕ´Ï´Ù. ±× °á°ú, ³ôÀº Ä¡·á È¿°ú¸¦ ¾òÀ» ¼ö ÀÖ°í, Ç¥Àû ¿Ü µ¶¼ºµµ ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ç×ü, ÆéƼµå, ¾ÐŸ¸Ó µîÀÇ ¸®°£µå¸¦ ÀÌ¿ëÇÑ Á¢ÇÕü ½Ã½ºÅÛÀÌ °³¹ßµÇ°í ÀÖÀ¸¸ç, HER2, EGFR, CD44 µîÀÇ ¾Ï ƯÀÌÀû ¼ö¿ëü¸¦ Àû±ØÀûÀ¸·Î Ç¥ÀûÈ­ÇÏ¿© °³º°È­ ¹× Á¤¹Ð ¾Ï Ä¡·á Àü·«À» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.

»õ·Î¿î ±â¼úÀº Ç×¾ÏÁ¦ Àü´Þ ´É·ÂÀ» ¾î¶»°Ô È®ÀåÇϰí Àִ°¡?

±â¼úÀû ¼ö·ÅÀº ¾Ï ¿µ¿ª¿¡¼­ NDDSÀÇ ¹üÀ§¿Í È¿´ÉÀ» ºü¸£°Ô Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. pH, ¿Âµµ, È¿¼Ò, »êȭȯ¿ø ±¸¹è µîÀÇ Àڱؿ¡ ¹ÝÀÀÇÏ´Â ½º¸¶Æ® ³ª³ëÀÔÀÚ´Â Á¾¾çÀÇ ¹Ì¼¼È¯°æ¿¡ ¸ÂÃá ¿Âµð¸Çµå ¾à¹° ¹æÃâÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î pH¿¡ ¹Î°¨ÇÑ ¸®Æ÷¼ØÀº ¼øÈ¯ Áß¿¡´Â ¾ÈÁ¤ÀûÀÌÁö¸¸ Á¾¾çÀÇ »ê¼º ȯ°æ¿¡¼­´Â ÆäÀ̷ε带 ¹æÃâÇÕ´Ï´Ù. ÀÚ±âÀ¯µµ ¾à¹° ¿î¹Ýü³ª ÃÊÀ½ÆÄ·Î ÃË¹ßµÈ ³ª³ë¹öºíµµ ÃÖ¼Ò Ä§½ÀÀû ±¹¼Ò Àü´ÞÀ» À§ÇØ ¿¬±¸ ÁßÀÔ´Ï´Ù.

¶Ç ´Ù¸¥ ÇÁ·ÐƼ¾î´Â À̹Ì¡ ±â´É°ú ¾à¹°Àü´ÞÀÇ ÅëÇÕÀ¸·Î, Áø´Ü°ú Ä¡·á¸¦ ÇϳªÀÇ ½Ã½ºÅÛ¿¡¼­ ¼öÇàÇÏ´Â ¼¼¶ó³ë½ºÆ½ Ç÷§ÆûÀ¸·Î À̾îÁý´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛ¿¡¼­´Â ¾à¹°ÀÇ ºÐÆ÷¿Í Á¾¾çÀÇ ¹ÝÀÀÀ» ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÀûÀÀÁõ¿¡ ¸Â´Â Ä¡·á ¿ä¹ýÀ» Àû¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áٱ⼼Æ÷¿Í ¼öÁö»ó ¼¼Æ÷¿¡¼­ À¯·¡ÇÑ ¿¢¼ÒÁ» ±â¹Ý Àü´Þ Ç÷§ÆûÀº Ÿ°í³­ »ýü ÀûÇÕ¼º°ú ¸é¿ª °¨Áö¸¦ ÇÇÇÒ ¼ö ÀÖ´Â ´É·ÂÀ¸·Î ÀÎÇØ ¾à¹° ¿î¼Û¿¡ ½ºÅÚ½º °°Àº Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÏ´Â °ÍÀ¸·Î ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù.

»ýºÐÇØ¼º ÇÏÀ̵å·Î°Ö, À̽ÄÇü Àú¼öÁö, ÈíÀÔÇü ³ª³ëÀÔÀÚ´Â Á¤¸Æ³» Åõ¿©¿¡ ±×Ä¡Áö ¾Ê°í Àü´Þ °æ·Î¸¦ È®ÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀ̰í, ±³¸ð¼¼Æ÷Á¾, ÃéÀå¾Ï, ´ëÀå¾Ï°ú °°Àº °íÇü¾Ï¿¡ ´ëÇÑ ±¹¼Ò ¼­¹æÇü Á¦Á¦¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. COVID-19 ¹é½ÅÀ¸·Î ´ëÁßÈ­µÈ mRNA žÀç ÁöÁú ³ª³ëÀÔÀÚ´Â ÇöÀç Á¾¾ç ƯÀÌÀû Ç׿øÀ» Àü´ÞÇϰí T¼¼Æ÷ ¹ÝÀÀÀ» ÀÚ±ØÇÏ´Â ¾Ï ¸é¿ªÄ¡·á¿¡ Àç»ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

NDDS µµÀÔÀ» ÁÖµµÇÏ´Â ¾ÏÀÇ À¯Çü°ú Ä¡·á¹ýÀº?

À¯¹æ¾Ï, Æó¾Ï, ³­¼Ò¾Ï, ÃéÀå¾Ï°ú °°Àº °íÇü¾ÏÀº ¸íÈ®ÇÑ ¹Ì¼¼È¯°æ°ú È®¸³µÈ ºÐÀÚ Ç¥ÀûÀ¸·Î ÀÎÇØ NDDS ÅëÇÕÀÇ ÃÖÀü¼±¿¡ ÀÖ½À´Ï´Ù. ¸®Æ÷Á»Çü µ¶¼Ò·çºñ½Å(µ¶½Ç µî)°ú ¾ËºÎ¹Î °áÇÕÇü ÆÄŬ¸®Å¹¼¿(¾Æºê¶ô»ê)Àº ±âÁ¸ È­Çпä¹ý ´ëºñ ¾ÈÀü¼º°ú ¹«ÁøÇà»ýÁ¸±â°£ÀÇ °³¼±À» º¸ÀÎ NDDSÀÇ »ó¾÷Àû ¼º°ø »ç·ÊÀÔ´Ï´Ù. ¾ÆÆ²¶ó½ºÁÖ¸¿ ¿¥Åº½Å(Ä«µµ»çÀ̶ó)°ú °°Àº HER2 Ç¥Àû Ç×ü¾à¹°Á¢ÇÕü(ADC)´Â ¼ö¿ëü °áÇÕ°ú ¼¼Æ÷³» ¼¼Æ÷µ¶¼ºÀ» ÅëÇÑ ÀÌÁß ÀÛ¿ëÀ¸·Î HER2 ¾ç¼º À¯¹æ¾Ï Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù.

¹éÇ÷º´À̳ª ¸²ÇÁÁ¾°ú °°Àº Ç÷¾× ¾Ç¼º Á¾¾çµµ ³ª³ëÀÔÀÚ ÀÎĸ½¶·¹ÀÌ¼Ç ¾à¹°À̳ª Ç¥Àû ´Ü¹éÁú ºÐÇØÁ¦ÀÇ ÇýÅÃÀ» ¹Þ°í ÀÖ½À´Ï´Ù. CAR-T ¼¼Æ÷Ä¡·áÁ¦³ª ¸é¿ª°ü¹®¾ïÁ¦Á¦´Â Á¾¾ç °ü·Ã ´ë½Ä¼¼Æ÷¸¦ Á¶ÀýÇϰųª ¸é¿ª¾ïÁ¦ À¯ÀüÀÚ¸¦ ÇÏÇâ Á¶ÀýÇÏ´Â siRNA¸¦ Àü´ÞÇϱâ À§ÇØ NDDS¿¡ ÀÇÇÑ Áö¿øÀÌ Á¡Á¡ ´õ ¸¹¾ÆÁö°í ÀÖ½À´Ï´Ù. ƯÈ÷ ÀüÀ̼º ¾Ï°ú ¾à¹° ³»¼º ¾Ï¿¡ ´ëÇÑ ¿¬±¸°¡ Ȱ¹ßÈ÷ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ´ÙÁ¦ º´¿ë ³ª³ëÀÔÀÚ ½Ã½ºÅÛÀº ¹èÃâ ÆßÇÁ¿Í Á¾¾çÀÇ ºÒ±ÕÀϼºÀ» ±Øº¹Çϱâ À§ÇØ °í¾ÈµÇ¾ú½À´Ï´Ù.

Áö¿ªÀûÀ¸·Î´Â ¹Ì±¹ÀÌ FDAÀÇ ½ÂÀΰú ±¹¸³¾Ï¿¬±¸¼ÒÀÇ ÀÚ±Ý Áö¿øÀ» ¹ÙÅÁÀ¸·Î ÀÓ»ó½ÃÇè Ȱµ¿°ú »ó¾÷Àû °³¹ß¿¡¼­ ¼±µÎ¸¦ ´Þ¸®°í ÀÖ½À´Ï´Ù. À¯·´Àº Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ °­·ÂÇÑ ±ÔÁ¦¸¦ ÅëÇØ À̸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â Áß±¹, ÀϺ», Çѱ¹°ú °°Àº ±¹°¡µéÀÌ ³ª³ëÀÇÇÐ ½ºÅ¸Æ®¾÷°ú Á¦Á¶ ÀÎÇÁ¶ó¿¡ ¸¹Àº ÅõÀÚ¸¦ ÅëÇØ Áö¿ª Çõ½Å°ú ¼¼°è ½ÃÀå ÁøÃâÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

¾Ï Ä¡·á¿¡¼­ NDDS ¼¼°è ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¾Ï Ä¡·á¿ë ½Å¾à Àü´Þ ½Ã½ºÅÛ ¼¼°è ½ÃÀå ¼ºÀåÀº ¾Ï ¹ßº´·ü Áõ°¡, ¾Ï Ä¡·áÁ¦ ÆÄÀÌÇÁ¶óÀÎÀÇ È®´ë, Ç¥Àû Ä¡·á¸¦ Áö¿øÇÏ´Â ÀÓ»óÀû Áõ°Å Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÃÖ¼Òħ½ÀÀûÀÌ°í °³ÀÎÈ­µÈ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 Çö´ë Á¾¾çÇÐÀÇ ¸ñÇ¥¿¡ ºÎÇÕÇϴ ÷´Ü Àü´Þ Ç÷§Æû¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Á¦¾à»çµéÀº NDDS¸¦ Ȱ¿ëÇÏ¿© ¾à¹°ÀÇ °³¼±À» ÅëÇÑ Æ¯Çã±â°£ ¿¬Àå, »õ·Î¿î ÀûÀÀÁõ ÁøÀÔ, È¥ÀâÇÑ Ä¡·á ȯ°æ¿¡¼­ÀÇ ÆÄÀÌÇÁ¶óÀÎ Â÷º°È­¸¦ ²ÒÇϰí ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ½ºÅ¸Æ®¾÷, ÇÐ°è ¿¬±¸¼Ò, Á¦¾à»ç °£ÀÇ Àü·«Àû Á¦ÈÞ´Â ½ÇÇè½Ç ±Ô¸ðÀÇ Çõ½Å¿¡¼­ ÀÓ»ó ¹× »ó¾÷Àû °³¹ß·Î À̾îÁö´Â Çõ½ÅÀÇ ¿©Á¤À» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹µµ Çõ½Å Ä¡·áÁ¦ ¹× Á¶±â ½ÂÀÎ °æ·Î¿¡ µû¶ó NDDS¸¦ ½ÂÀÎÇÔÀ¸·Î½á À¯¿¬¼ºÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ °á°ú ±â¹Ý ¸ðµ¨¿¡ ´ëÇÑ ÁöºÒÀÚÀÇ °ü½ÉÀº °íºñ¿ëÀÌÁö¸¸ È¿´ÉÀÌ ³ôÀº NDDS Ä¡·áÁ¦¿¡ À¯¸®ÇÑ »óȯ ȯ°æÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ ºÐ¼®°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿°¡ ȯÀÚ °èÃþÈ­¸¦ °³¼±ÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº Á¤¹Ð Á¾¾çÇÐÀÇ ±âÃʰ¡ µÉ °ÍÀÔ´Ï´Ù. Àç·á°úÇÐ, »ý¸í°øÇÐ, AI¸¦ Ȱ¿ëÇÑ ¾à¹° ÃÖÀûÈ­ Ä¡·á·Î ¾Ï Ä¡·á¿ë NDDS ½ÃÀåÀº ¿©·¯ Á¾¾ç À¯Çü, Ä¡·á ȯ°æ, Áö¿ª¿¡ °ÉÃÄ °­·ÂÇÏ°Ô È®´ëµÉ ż¼¸¦ °®Ãß°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(³ª³ëÀÔÀÚ, »öÀüÀÔÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå°ú °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Novel Drug Delivery Systems in Cancer Therapy Market to Reach US$64.5 Billion by 2030

The global market for Novel Drug Delivery Systems in Cancer Therapy estimated at US$21.3 Billion in the year 2024, is expected to reach US$64.5 Billion by 2030, growing at a CAGR of 20.3% over the analysis period 2024-2030. Nanoparticles, one of the segments analyzed in the report, is expected to record a 18.0% CAGR and reach US$35.8 Billion by the end of the analysis period. Growth in the Embolization Particles segment is estimated at 23.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.8 Billion While China is Forecast to Grow at 26.9% CAGR

The Novel Drug Delivery Systems in Cancer Therapy market in the U.S. is estimated at US$5.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$15.0 Billion by the year 2030 trailing a CAGR of 26.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.4% and 18.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.9% CAGR.

Global Novel Drug Delivery Systems in Cancer Therapy - Key Trends & Drivers Summarized

Why Are Traditional Cancer Treatments Being Disrupted by Novel Drug Delivery Systems?

Conventional chemotherapy has long been plagued by systemic toxicity, poor bioavailability, and lack of tumor specificity-issues that compromise treatment efficacy and patient quality of life. Novel drug delivery systems (NDDS) are rapidly emerging as transformative technologies in oncology, offering targeted delivery of anticancer agents directly to tumor sites while minimizing damage to healthy tissues. By enhancing pharmacokinetics and overcoming drug resistance mechanisms, NDDS have redefined how clinicians approach complex and heterogeneous cancer types.

Among the most significant innovations are nanocarriers such as liposomes, dendrimers, micelles, and polymeric nanoparticles, which encapsulate cytotoxic agents and enable controlled release at the tumor microenvironment. These systems exploit the Enhanced Permeability and Retention (EPR) effect observed in solid tumors to achieve site-specific delivery. The result is a higher therapeutic index and reduced off-target toxicity. Additionally, conjugated systems using ligands such as antibodies, peptides, or aptamers are being developed to achieve active targeting of cancer-specific receptors like HER2, EGFR, and CD44, thereby enabling personalized and precision oncology strategies.

How Are Emerging Technologies Expanding Capabilities in Cancer Drug Delivery?

Technological convergence is rapidly enhancing the scope and efficacy of NDDS in oncology. Smart nanoparticles that respond to stimuli such as pH, temperature, enzymes, or redox gradients are enabling on-demand drug release, tailored to the tumor’s microenvironment. pH-sensitive liposomes, for instance, remain stable in circulation but release payloads in the acidic milieu of tumors. Magnetically guided drug carriers and ultrasound-triggered nanobubbles are also under investigation for localized delivery with minimal invasiveness.

Another frontier is the integration of imaging capabilities with drug delivery, leading to theranostic platforms that combine diagnosis and therapy in a single system. These systems allow for real-time monitoring of drug distribution and tumor response, enabling adaptive treatment regimens. Additionally, exosome-based delivery platforms derived from stem cells or dendritic cells are being explored for their innate biocompatibility and ability to bypass immune detection, providing a stealth-like approach to drug transport.

Biodegradable hydrogels, implantable reservoirs, and inhalable nanoparticles are extending delivery routes beyond intravenous administration. These systems improve patient compliance and enable localized, sustained-release formulations for solid tumors such as glioblastoma, pancreatic, and colorectal cancers. mRNA-loaded lipid nanoparticles, popularized by COVID-19 vaccines, are now being repurposed for cancer immunotherapy to deliver tumor-specific antigens and stimulate T-cell responses.

Which Cancer Types and Therapies Are Leading Adoption of NDDS?

Solid tumors such as breast, lung, ovarian, and pancreatic cancers are at the forefront of NDDS integration due to their well-defined microenvironments and established molecular targets. Liposomal doxorubicin (e.g., Doxil) and albumin-bound paclitaxel (Abraxane) are commercially successful examples of NDDS that have demonstrated improved safety and progression-free survival compared to traditional chemotherapies. HER2-targeted antibody-drug conjugates (ADCs), such as ado-trastuzumab emtansine (Kadcyla), are revolutionizing treatment for HER2-positive breast cancer, offering dual action through receptor binding and intracellular cytotoxicity.

Hematological malignancies like leukemia and lymphoma are also benefiting from nanoparticle-encapsulated drugs and targeted protein degraders. CAR-T cell therapy and immune checkpoint inhibitors are increasingly being supported by NDDS to modulate tumor-associated macrophages or deliver siRNA that downregulates immunosuppressive genes. Research is particularly intense in metastatic and drug-resistant cancers, where multi-drug nanoparticle systems are being engineered to overcome efflux pumps and tumor heterogeneity.

Regionally, the United States leads in both clinical trial activity and commercial deployment, supported by FDA approvals and National Cancer Institute funding. Europe follows with strong regulatory backing for precision medicine initiatives. In Asia-Pacific, countries like China, Japan, and South Korea are investing heavily in nanomedicine startups and manufacturing infrastructure to accelerate local innovation and global market participation.

What Is Fueling Growth in the Global Market for NDDS in Cancer Therapy?

The growth in the global novel drug delivery systems market for cancer therapy is driven by several factors, including escalating cancer prevalence, expanding oncology drug pipelines, and increasing clinical evidence supporting targeted therapies. Rising demand for minimally invasive, personalized treatment options has catalyzed investment in advanced delivery platforms that align with modern oncology goals.

Pharmaceutical companies are leveraging NDDS to extend patent life through drug reformulation, enter new indications, and differentiate their pipelines in a crowded therapeutic landscape. Strategic collaborations between biotech startups, academic labs, and pharmaceutical giants are accelerating the translational journey from lab-scale innovation to clinical and commercial deployment. Regulatory agencies are also demonstrating flexibility by approving NDDS under breakthrough therapy and accelerated approval pathways.

Moreover, payer interest in outcomes-based models is creating a favorable reimbursement climate for high-cost but high-efficacy NDDS therapies. As data analytics and digital biomarkers improve patient stratification, these systems will become cornerstones of precision oncology. With advances in materials science, bioengineering, and AI-driven drug optimization, the NDDS market in cancer therapy is poised for robust expansion across multiple tumor types, treatment settings, and geographies.

SCOPE OF STUDY:

The report analyzes the Novel Drug Delivery Systems in Cancer Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Nanoparticles, Embolization Particles)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â